MedTrace Logo

Tofatib Treatment for IgG4-related Disease

NCT05625581 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-11-23

No results posted yet for this study

Summary

Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.

Conditions

Interventions

DRUG

tofacitinib

All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Gao Jie, doctor · Changhai Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05625581 on ClinicalTrials.gov